Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Addex Therapeutics

www.addextherapeutics.com

Latest From Addex Therapeutics

Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business

Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.

Deals Business Strategies

Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline

Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.

Commercial Companies

Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri

The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.

Approvals Launches

Execs On The Move, December 2016

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Addex Pharmaceuticals Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Addex Therapeutics
  • Senior Management
  • Tim Dyer, CEO
    Roger G Mills, MD, CMO
    Robert Lutjens, PhD, CSO
  • Contact Info
  • Addex Therapeutics
    Phone: (41) 22 884 1555
    12, chemin des Aulx
    Plan-les-Ouates, Geneva, 1228
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register